

Applicant : Timothy Vollmer
Serial No. : 10/556,454
Filing Date : November 11, 2005
Page 2 of 10 of Response to April 13, 2010 Office Action

Amendments to the Claims:

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of treating a subject afflicted with a form of multiple sclerosis comprising administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the administration of the mitoxantrone substantially precedes the administration of the glatiramer acetate, and wherein such administration is effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject.
2. (Original) The method of claim 1, wherein the form of multiple sclerosis is relapsing-remitting multiple sclerosis.
3. (Previously Presented) The method of claim 1, wherein the subject is a human being.
4. (Previously Presented) The method of claim 1, wherein each of the amount of glatiramer acetate when taken alone, and the amount of mitoxantrone when taken alone is effective to alleviate the symptom of the form of multiple sclerosis.
5. Cancelled
6. (Previously Presented) The method of claim 1, wherein the symptom is the frequency of relapses, the frequency of clinical exacerbation, or the accumulation of physical disability.

Applicant : Timothy Vollmer
Serial No. : 10/556,454
Filing Date : November 11, 2005
Page 3 of 10 of Response to April 13, 2010 Office Action

7. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 10 to 600 mg/week.
8. (Original) The method of claim 7, wherein the amount of glatiramer acetate is 300 mg/week.
9. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 50 to 150 mg/day.
10. (Original) The method of claim 9, wherein the amount of glatiramer acetate is 100 mg/day.
11. (Previously Presented) The method of claim 1, wherein the amount of glatiramer acetate is in the range from 10 to 80 mg/day.
12. (Original) The method of claim 11, wherein the amount of glatiramer acetate is 20 mg/day.
13. (Previously Presented) The method of claim 1, wherein the periodic administration of glatiramer acetate is effected daily.
- 14-18. Cancelled
19. (Previously Presented) The method of claim 1, wherein the administration of the glatiramer acetate is effected subcutaneously and the administration of the mitoxantrone is effected intravenously.
20. (Original) A pharmaceutical composition comprising an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to

Applicant : Timothy Vollmer
Serial No. : 10/556,454
Filing Date : November 11, 2005
Page 4 of 10 of Response to April 13, 2010 Office Action

alleviate a symptom of a form of multiple sclerosis in a subject.

21. (Original) The pharmaceutical composition of claim 20, wherein each of the amount of glatiramer acetate when taken alone and the amount of mitoxantrone when taken alone is effective to alleviate the symptom of multiple sclerosis.
22. Cancelled
23. (Original) A package comprising
a first pharmaceutical composition comprising an amount of glatiramer acetate and a pharmaceutically acceptable carrier;
a second pharmaceutical composition comprising an amount of mitoxantrone and a pharmaceutically acceptable carrier; and
instructions for use of the first and second pharmaceutical compositions together to alleviate a symptom of a form of multiple sclerosis in a subject.
24. (Original) The package of claim 23, wherein the amount of glatiramer acetate is 300 mg.
25. (Original) The package of claim 23, wherein the amount of glatiramer acetate is 20 mg.
26. Cancelled
27. (Previously Presented) The method of claim 1 wherein the reduction of the accumulation of Gd-enhancing lesions in the subject is greater than the reduction of the accumulation of Gd-enhancing lesions in a subject treated with glatiramer acetate alone.
28. (Previously Presented) The method of claim 1 wherein the

Applicant : Timothy Vollmer
Serial No. : 10/556,454
Filing Date : November 11, 2005
Page 5 of 10 of Response to April 13, 2010 Office Action

reduction in relapse rate in the subject is greater than the reduction in relapse rate in a subject treated with glatiramer acetate alone.

29. (Previously Presented) The method of claim 4 wherein the efficacy of glatiramer acetate is enhanced.
30. (New) A method of treating a subject afflicted with a form of multiple sclerosis comprising administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the administration of mitoxantrone precedes the administration of glatiramer acetate by approximately 2 weeks through approximately 10 weeks, and wherein such administration is effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject.
31. (New) A method of treating a subject afflicted with a form of multiple sclerosis and treated by mitoxantrone administration, comprising administering, by daily subcutaneous injection, glatiramer acetate two weeks after the last administration of mitoxantrone, wherein the amounts of mitoxantrone and glatiramer acetate are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject.